- Home
- Publications
- Publication Search
- Publication Details
Title
The Glycome of Normal and Malignant Plasma Cells
Authors
Keywords
Gene expression, Myeloma cells, Plasma cells, Sulfates, Myelomas, Bone marrow cells, Multiple myeloma, Biosynthesis
Journal
PLoS One
Volume 8, Issue 12, Pages e83719
Publisher
Public Library of Science (PLoS)
Online
2013-12-27
DOI
10.1371/journal.pone.0083719
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma
- (2013) Rogier M. Reijmers et al. FEBS Journal
- Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease
- (2012) M. Andrulis et al. HAEMATOLOGICA
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- Gene Expression Profiling in Multiple Myeloma--Reporting of Entities, Risk, and Targets in Clinical Routine
- (2011) T. Meissner et al. CLINICAL CANCER RESEARCH
- SULFs in human neoplasia: implication as progression and prognosis factors
- (2011) Caroline Bret et al. Journal of Translational Medicine
- Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling
- (2010) Martina Willhauck-Fleckenstein et al. ANGIOGENESIS
- Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
- (2010) B. Nair et al. BLOOD
- Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays
- (2010) Karène Mahtouk et al. BMC CANCER
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
- (2010) D. Hose et al. HAEMATOLOGICA
- The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
- (2010) NATURE BIOTECHNOLOGY
- Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
- (2009) D. Hose et al. BLOOD
- The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
- (2009) Anne Catherine Sprynski et al. BLOOD
- Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma
- (2009) R. M. Reijmers et al. BLOOD
- Induction of angiogenesis by normal and malignant plasma cells
- (2009) D. Hose et al. BLOOD
- TP53deletion is not an adverse feature in multiple myeloma treated with total therapy 3
- (2009) John D. Shaughnessy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells
- (2009) Caroline Bret et al. BRITISH JOURNAL OF HAEMATOLOGY
- APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
- (2009) Jérôme Moreaux et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
- (2009) Jean-Luc Harousseau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis
- (2009) A Seckinger et al. ONCOGENE
- The Glycosylphosphatidylinositol Anchor: A Complex Membrane-Anchoring Structure for Proteins†
- (2008) Margot G. Paulick et al. BIOCHEMISTRY
- Glypicans
- (2008) Jorge Filmus et al. GENOME BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started